Biosante wins $250,000 research contract
Drug developer Biosante has been awarded a $250,000 (€210,000) subcontract from the University of Nebraska, Lincoln (UNL), to develop recombinant Factor IX (FIX) formulations for delivery via alternative routes of administration, which, if successful,...